A Grand Rapids company has been selected by the U.S. Department of Health and Human Services and the U.S. Department of Defense to support the expansion of the country’s capacity for manufacturing and distributing vaccines or therapeutics related to the COVID-19 pandemic.
Grand River Aseptic Manufacturing is a parenteral contract development and manufacturing organization. It provides the capacity to perform advanced aseptic fill and finish services, the last two steps in the manufacturing process for vaccines or other therapeutics.
“We are extremely honored to be chosen to serve our country and help respond to the demands and challenges presented by the COVID-19 pandemic,” says Tom Ross, president and CEO of Grand River. “As a homegrown company with a strong culture built on teamwork and accountability, our team will confidently deliver the safest and highest-quality solutions that will ultimately be life-saving for the American people.”
Through the public-private partnership, the federal government is reserving fill and finish capacity on a commercial filling line for use by federal partners that are developing COVID-19 vaccines or therapeutic treatments.
The contract was awarded as a collaboration among the Biomedical Advances Research and Development Authority, part of the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, and the Army Contracting Command.
Grand River will use its new 60,000-square-foot large-scale fill and finish facility located in Grand Rapids. The company has three manufacturing facilities and more than 100,000 square feet of production space.